Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB announces Neupro approval recommendation

UCB announces Neupro approval recommendation

25th April 2008

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that marketing authorisation be granted for Neupro (rogtigotine transdermal patch) to treat Restless Legs Syndrome (RLS).

A positive opinion on the use of the drug to treat moderate to severe idiopathic RLS in adults was reached following two clinical trials evaluating the use of Neupro over a six-month period, in which it was found to improve RLS symptoms.

UCB’s president of CNS operations, Troy Cox, said the CHMP recommendation to approve the drug for marketing was “encouraging news” and he added that the pharmaceutical firm intends to file a RLS manufacturing variation with the European Medicines Agency.

“We are looking forward to making Neupro available as a new therapeutic option to people living with this chronic neurological disorder,” he said.

UCB claims to be the “leader” in pharmaceutical solutions for people suffering from epilepsy and allergies. According to its website, the firm is currently working on developing treatments for multiple sclerosis, Crohn’s disease and osteoperosis.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.